Subscribe Us

header ads

Recents

header ads

Generic Drugs Market Size, Growth, Demands Outlook and Forecasts to 2030

Precedence Research - December 30, 2022

According to the research report, the global genericdrugs market size is expected to touch USD 670.82 Billion by 2030, from USD 439.37 Billion in 2022, growing with a significant CAGR of 5.4% from 2022 to 2030.

Generic Drugs Market Size 2022 to 2030

The generic drugs market report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global generic drugs market in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global generic drugs market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global generic drugs market during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1205

 Report Scope of the Generic Drugs Market

Report HighlightsDetails
Market SizeUS$ 670.82 Billion by 2030
Growth RateCAGR of 5.4% From 2022 to 2030
Base Year2021
Historic Data2017 to 2021
Forecast Period2022 to 2030
Segments CoveredDrug, Brand, Route of Drug Administration, Therapeutic Application, Distribution Channel
Regional ScopeNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

This study covers a detailed segmentation of the global generic drugs market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global generic drugs market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • Mylan N.V.
  • Abbott Laboratories
  • ALLERGAN
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • STADA Arzneimittel AG
  • GlaxoSmithKline Plc.
  • Baxter International Inc.
  • Pfizer Inc.
  • Sandoz International GmbH

Market Segmentation

 By Brand

  • Pure generic drugs
  • Branded generic drugs

By Route of Drug Administration

  • Oral
  • Topical
  • Parental
  • Others

By Therapeutic Application

  • Central nervous system (CNS)
  • Cardiovascular
  • Dermatology
  • Oncology
  • Respiratory
  • Others

Key Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global generic drugs market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global generic drugs market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Generic Drugs Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Generic Drugs Market

5.1. Covid-19: generic drugs Industry Impact

5.2. generic drugs Business Impact Assessment: Covid-19

5.2.1. Services Challenges/Disruption

5.2.2. Market Trends and generic drugs Opportunities in the COVID-19 Landscape for Major Markets

5.3. Strategic Measures against Covid-19

5.3.1. Government Support and Initiative to Combat Covid-19

5.3.2. Proposal for generic drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Generic Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.1.1. The low cost of generics, as an alternative to branded drugs

6.1.1.2. Large number of patent expired branded drugs

6.1.1.3. Initiatives by governments and other regulatory bodies

6.1.2. Market Restraints

6.1.2.1. Stringent governmental regulations and adverse effects associated with drugs

6.1.3. Market Opportunities

6.1.3.1. Use of RPA to ensure regulatory and standards compliance

Chapter 7. Global Generic Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.1.1. generic drugs Market Revenue by Market Players (2017 - 2021)

7.1.1.2. generic drugs Market Revenue Market Share by Market Players (2017 - 2021)

7.1.2. Key Organic/Inorganic Strategies Adopted by Players

7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation

7.1.2.2. Merger and Acquisition, Collaboration and Partnerships

7.1.3. Market Players Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of End-users

Chapter 8. Global Generic Drugs Market, By Drug Type

8.1. generic drugs Market, by Drug Type, 2017-2030

8.1.1. Simple Generics

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Super Generics

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Generic Drugs Market, By Brand

9.1. generic drugs Market, by Brand, 2017-2030

9.1.1. Pure generic drugs

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Branded generic drugs

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Generic Drugs Market, By Route of Drug Administration

10.1. generic drugs Market, by Route of Drug Administration, 2017-2030

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Topical

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Parental

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Generic Drugs Market, By Therapeutic Application

11.1. generic drugs Market, by Therapeutic Application, 2017-2030

11.1.1. Central nervous system (CNS)

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Cardiovascular

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Dermatology

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Oncology

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Respiratory

11.1.5.1. Market Revenue and Forecast (2017-2030)

11.1.6. Others

11.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Generic Drugs Market, By Distribution Channel

12.1. generic drugs Market, by Distribution Channel, 2017-2030

12.1.1. Hospitals Pharmacies

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Retail Pharmacies

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Others

12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue Forecast by Drug Type(2017-2030)

13.1.2. Market Revenue Forecast by Brand (2017-2030)

13.1.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.1.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.1.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.1.6. U.S

13.1.6.1. Market Revenue Forecast (2017-2030)

13.1.7. Canada

13.1.7.1. Market Revenue Forecast (2017-2030)

13.2. Europe

13.2.1. Market Revenue Forecast by Drug Type (2017-2030)

13.2.2. Market Revenue Forecast by Brand (2017-2030)

13.2.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.2.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.2.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.2.6. UK

13.2.6.1. Market Revenue Forecast (2017-2030)

13.2.7. Germany

13.2.7.1. Market Revenue Forecast (2017-2030)

13.2.8. France

13.2.8.1. Market Revenue Forecast (2017-2030)

13.2.9. Rest of EU

13.2.9.1. Market Revenue Forecast (2017-2030)

13.3. Asia Pacific (APAC)

13.3.1. Market Revenue Forecast by Drug Type (2017-2030)

13.3.2. Market Revenue Forecast by Brand (2017-2030)

13.3.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.3.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.3.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.3.6. China

13.3.6.1. Market Revenue Forecast (2017-2030)

13.3.7. India

13.3.7.1. Market Revenue Forecast (2017-2030)

13.3.8. Japan

13.3.8.1. Market Revenue Forecast (2017-2030)

13.3.9. Rest of APAC

13.3.9.1. Market Revenue Forecast (2017-2030)

13.4. LATAM

13.4.1. Market Revenue Forecast by Drug Type (2017-2030)

13.4.2. Market Revenue Forecast by Brand (2017-2030)

13.4.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.4.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.4.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.4.6. Brazil

13.4.6.1. Market Revenue Forecast (2017-2030)

13.4.7. Rest of LATAM

13.4.7.1. Market Revenue Forecast (2017-2030)

13.5. Middle East and Africa (MEA)

13.5.1. Market Revenue Forecast by Drug Type (2017-2030)

13.5.2. Market Revenue Forecast by Brand (2017-2030)

13.5.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.5.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.5.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.5.6. GCC

13.5.6.1. Market Revenue Forecast (2017-2030)

13.5.7. North Africa

13.5.7.1. Market Revenue Forecast (2017-2030)

13.5.8. South Africa

13.5.8.1. Market Revenue Forecast (2017-2030)

13.5.9. Rest of MEA

13.5.9.1. Market Revenue Forecast (2017-2030)

Chapter 14. Company Profiles

14.1. Abbott Laboratories

14.1.1. Company Overview, Business Information, Regional Presence

14.1.2. Product Portfolio Analysis

14.1.2.1. Product Details, Specification, Application

14.1.3. Revenue, Price, and Gross Margin (2017-2021)

14.1.4. Recent Developments and Strategies

14.2. Teva Pharmaceutical Industries Ltd.

14.2.1. Company Overview, Business Information, Regional Presence

14.2.2. Product Portfolio Analysis

14.2.2.1. Product Details, Specification, Application

14.2.3. Revenue, Price, and Gross Margin (2017-2021)

14.2.4. Recent Developments and Strategies

14.3. ALLERGAN

14.3.1. Company Overview, Business Information, Regional Presence

14.3.2. Product Portfolio Analysis

14.3.2.1. Product Details, Specification, Application

14.3.3. Revenue, Price, and Gross Margin (2017-2021)

14.3.4. Recent Developments and Strategies

14.4. Sandoz International GmbH

14.4.1. Company Overview, Business Information, Regional Presence

14.4.2. Product Portfolio Analysis

14.4.2.1. Product Details, Specification, Application

14.4.3. Revenue, Price, and Gross Margin (2017-2021)

14.4.4. Recent Developments and Strategies

14.5. Mylan N.V.

14.5.1. Company Overview, Business Information, Regional Presence

14.5.2. Product Portfolio Analysis

14.5.2.1. Product Details, Specification, Application

14.5.3. Revenue, Price, and Gross Margin (2017-2021)

14.5.4. Recent Developments and Strategies

14.6. STADA Arzneimittel AG

14.6.1. Company Overview, Business Information, Regional Presence

14.6.2. Product Portfolio Analysis

14.6.2.1. Product Details, Specification, Application

14.6.3. Revenue, Price, and Gross Margin (2017-2021)

14.6.4. Recent Developments and Strategies

14.7. Baxter International Inc.

14.7.1. Company Overview, Business Information, Regional Presence

14.7.2. Product Portfolio Analysis

14.7.2.1. Product Details, Specification, Application

14.7.3. Revenue, Price, and Gross Margin (2017-2021)

14.7.4. Recent Developments and Strategies

14.8. Eli Lilly and Company

14.8.1. Company Overview, Business Information, Regional Presence

14.8.2. Product Portfolio Analysis

14.8.2.1. Product Details, Specification, Application

14.8.3. Revenue, Price, and Gross Margin (2017-2021)

14.8.4. Recent Developments and Strategies

14.9. GlaxoSmithKline Plc.

14.9.1. Company Overview, Business Information, Regional Presence

14.9.2. Product Portfolio Analysis

14.9.2.1. Product Details, Specification, Application

14.9.3. Revenue, Price, and Gross Margin (2017-2021)

14.9.4. Recent Developments and Strategies

14.10. Pfizer Inc.

14.10.1. Company Overview, Business Information, Regional Presence

14.10.2. Product Portfolio Analysis

14.10.2.1. Product Details, Specification, Application

14.10.3. Revenue, Price, and Gross Margin (2017-2021)

14.10.4. Recent Developments and Strategies

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Tags:

Post a Comment

0 Comments